title: Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction.
abstract: OBJECTIVE
  The purpose of this study was to compare the ability of human CD34(+) hematopoietic stem cells and bone marrow mesenchymal stem cells (MSC) to treat myocardial infarction (MI) in a model of permanent left descendent coronary artery (LDA) ligation in nude rats.
  
  
  BACKGROUND
  Transplantation of human CD34(+) cells and MSC has been proved to be effective in treating MI, but no comparative studies have been performed to elucidate which treatment prevents left ventricular (LV) remodelling more efficiently.
  
  
  METHODS
  Human bone marrow MSC or freshly isolated CD34(+) cells from umbilical cord blood were injected intramyocardially in infarcted nude rats. Cardiac function was analyzed by echocardiography. Ventricular remodelling was evaluated by tissue histology and electron microscopy, and neo-formed vessels were quantified by immunohistochemistry. Chronic local inflammatory infiltrates were evaluated in LV wall by hematoxylin-eosin staining. Apoptosis of infarcted tissue was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling assay.
  
  
  RESULTS
  Both cell types induced an improvement in LV cardiac function and increased tissue cell proliferation in myocardial tissue and neoangiogenesis. However, MSC were more effective for the reduction of infarct size and prevention of ventricular remodelling. Scar tissue was 17.48 +/- 1.29% in the CD34 group and 10.36 +/- 1.07% in the MSC group (p < 0.001 in MSC vs. CD34). Moreover, unlike MSC, CD34(+)-treated animals showed local inflammatory infiltrates in LV wall that persisted 4 weeks after transplantation.
  
  
  CONCLUSIONS
  Mesenchymal stem cells might be more effective than CD34(+) cells for the healing of the infarct. This study contributes to elucidate the mechanisms by which these cell types operate in the course of MI treatment.
authors.affiliation: Fundación para la Investigación Hospital Universitario La Fe, Valencia, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Armiñán
authors.forename: Carolina
authors.initials: C
authors.lastname: Gandía
authors.forename: J Manuel
authors.initials: JM
authors.lastname: García-Verdugo
authors.forename: Elisa
authors.initials: E
authors.lastname: Lledó
authors.forename: César
authors.initials: C
authors.lastname: Trigueros
authors.forename: Amparo
authors.initials: A
authors.lastname: Ruiz-Saurí
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Miñana
authors.forename: Pilar
authors.initials: P
authors.lastname: Solves
authors.forename: Rafael
authors.initials: R
authors.lastname: Payá
authors.forename: J Anastasio
authors.initials: JA
authors.lastname: Montero
authors.forename: Pilar
authors.initials: P
authors.lastname: Sepúlveda
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism / Q000627:therapeutic use; D049109:Cell Proliferation; D018380:Hematopoietic Stem Cell Transplantation; D007150:Immunohistochemistry; D045164:Mesenchymal Stem Cell Transplantation; D009203:Myocardial Infarction / Q000628:therapy*; D019899:Paracrine Communication / Q000502:physiology; D051381:Rats; D011923:Rats, Nude; D016277:Ventricular Function, Left
chemical_list: D018952:Antigens, CD34